PARP1 and neoplasm: The radiosensitising effect of the PARP inhibitor olaparib on tumours has been reported in pre-clinical lung cancer models.11,29,30 However, the effect of olaparib and thoracic radiation on normal tissue toxicity has rarely been assessed in vivo.